QTc Prolongation Risk with Sertraline and Ondansetron Co-Administration

Understanding the Individual Drug Risks

• The American Academy of Child and Adolescent Psychiatry recommends caution when using sertraline due to its potential to interact with other QT-prolonging drugs, although it has a lower QTc prolongation risk compared to other SSRIs like citalopram 1
• Ondansetron is listed as a QT-prolonging antiemetic in pediatric emergency medicine guidelines, appearing on comprehensive lists of medications that increase arrhythmia risk, according to guidelines from the American Academy of Pediatrics 2, 3

Combined Risk Assessment

• The British Thoracic Society explicitly recommends avoiding concomitant use of ondansetron with other QT-prolonging medications, including antiarrhythmics, antimalarials, antipsychotics, and certain antidepressants 5
• The European Society of Cardiology states that avoidance of treatment with more than one drug prolonging the QT interval is recommended, and evaluation of the QT interval before initiation and during dose titration should be considered 6

Clinical Management Algorithm

• The European Society of Cardiology recommends checking serum potassium and magnesium levels and correcting hypokalemia or hypomagnesemia before drug administration 6
• The American Academy of Pediatrics guidelines note that review of all concomitant medications for additional QT-prolonging agents is necessary, as the risk increases with each additional drug 2, 3, 5

Additional Consideration: Serotonin Syndrome Risk

• The American Academy of Child and Adolescent Psychiatry warns that serotonin syndrome has been reported with 5-HT3 receptor antagonists, particularly when combined with SSRIs like sertraline, and recommends monitoring for mental status changes, autonomic instability, neuromuscular symptoms, and gastrointestinal symptoms 1